From: Red blood cell transfusion in the resuscitation of septic patients with hematological malignancies
Characteristics | No RBC transfusion (n = 421) | RBC transfusion (n = 210) | p |
---|---|---|---|
Demographics | |||
Age (years) | 60 [49–71] | 60 [49–69] | 0.68 |
Male gender | 268 (63.7%) | 138 (65.7%) | 0.30 |
Comorbid illnesses | |||
Performance status 3–4 | 87 (20.7%) | 51 (24.3%) | 0.35 |
Charlson comorbidity index | 4 [3–6] | 4 [2–5] | 0.77 |
Cardiovascular comorbidity | 155 (36.8%) | 77 (36.7%) | 1 |
Coronary disease | 31 (7.3%) | 19 (9.0%) | 0.53 |
Chronic heart failure | 20 (4.8%) | 14 (6.7%) | 0.35 |
Peripheral arterial disease | 19 (4.5%) | 6 (2.8%) | 0.39 |
Underlying malignancy | 0.01 | ||
Non-Hodgkin lymphoma | 149 (35.4%) | 53 (25.2%) | |
Hodgkin lymphoma | 13 (3.1%) | 2 (1.0%) | |
Chronic lymphocytic leukemia | 37 (8.8%) | 13 (6.2%) | |
Acute lymphocytic leukemia | 23 (5.5%) | 20 (9.5%) | |
Acute myeloid leukemia | 88 (20.9%) | 69 (32.3%) | |
Chronic myeloid leukemia | 8 (1.9%) | 4 (1.9%) | |
Myeloma | 56 (13.3%) | 26 (12.4%) | |
Myelodysplastic syndrome | 23 (5.5%) | 12 (5.7%) | |
Others | 24 (5.7%) | 11 (5.2%) | |
Time between diagnosis and ICU admission (days) | 294 [38–1309] | 199 [29–817] | 0.06 |
Hematopoietic stem cell transplantation | |||
Autologous | 50 (11.9%) | 26 (12.4%) | 0.72 |
Allogeneic | 77 (18.3%) | 33 (15.7%) | 0.49 |
Malignancy status | |||
Newly diagnosed | 120 (28.6%) | 70 (33.3%) | 0.95 |
Partial/complete remission | 115 (27.5%) | 54 (25.7%) | 0.54 |
Time between hospital and ICU admissions (days) | 6 [1–21] | 8 [1–19] | 0.38 |
ICU admission characteristics | |||
SOFA | 6 [4–9] | 8 [5–11] | <0.001 |
Hemoglobin (g/dL) | 9.7 [8.7–11] | 7.8 [7.1–8.8] | <0.001 |
Hemoglobin ranges [n (%)] | 0.001 | ||
>9 g/dL | 259 (66.1%) | 44 (21.9%) | |
7–9 g/dL | 126 (32.1%) | 117 (58.2%) | |
<7 g/dL | 7 (1.8%) | 40 (19.9%) | |
Platelet count (G/L) | 77 [32–170] | 31 [16–63] | <0.001 |
Neutropenia | 122 (29.0%) | 107 (51.0%) | <0.001 |
Lactate level (mmol/L) | 2.0 [1.2–3.7] | 2.3 [1.5–4.9] | 0.02 |
Source of infection | |||
Pneumonia | 252 (59.9%) | 106 (50.5%) | 0.03 |
Abdominal | 15.7% | 17.6% | 0.61 |
Urinary tract | 26 (6.2%) | 10 (4.8%) | 0.59 |
Catheter-related | 5.0% | 3.3% | 0.46 |
Pathogens | |||
Gram-negative bacteria | 108 (25.7%) | 67 (31.9%) | 0.12 |
Gram-positive bacteria | 60 (14.3%) | 21 (10.0%) | 0.69 |
Aspergillus | 46 (10.9%) | 23 (11.0%) | 1.00 |
Pneumocystis | 20 (4.8%) | 2 (1.0%) | 0.02 |
Life-supporting interventions | |||
Vasopressive drugs | 243 (57.7%) | 147 (70%) | 0.004 |
Invasive ventilation | 205 (48.7%) | 116 (55.2%) | 0.01 |
Renal replacement therapy | 92 (22.2%) | 62 (30.5%) | 0.03 |
Platelet transfusions | |||
Day 1 | 70 (16.6%) | 96 (45.7%) | <0.001 |
Day 2 | 58 (13.7%) | 82 (39.0%) | <0.001 |
Mortality | |||
ICU mortality | 106 (25.2%) | 82 (39.0%) | <0.001 |
Hospital mortality | 154 (36.6%) | 107 (51.0%) | <0.001 |